However, the currently used serum tumor biomarkers, carbohydrate antigen 19-9 and carcinoembryonic antigen (CEA), have shown a low positive rate and poor sensitivity toward the early-stage CRC. The gene discussed is CEACAM5; the disease is neoplasm.